Login
$AGIO
$29.55 -$0.60 (1.99%) After hours

$AGIO SEC Filings

Filed On Filing
16 Nov 2026 SCHEDULE 13G/A
16 Nov 2026 SCHEDULE 13G/A
13 Nov 2026 SCHEDULE 13G
05 Nov 2026 10-Q
05 Nov 2026 8-K: Results of Operations and Financial Condition

CAMBRIDGE, Mass., Nov. 5, 2026 – Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced financial results and u...

28 Oct 2026 Form 4: Gheuens Sarah, Chief Medical Officer

Received 7,866 shares by exercise or conversion ($197K) · Sold 7,866 shares ($296K)

26 Oct 2026 144
23 Oct 2026 Form 4: Gheuens Sarah, Chief Medical Officer

Received 1,489 shares by exercise or conversion ($37.2K) · Sold 1,489 shares ($55.9K) · Received 500 shares by exercise or conversion ($12.5K) · 1 more

22 Oct 2026 144
21 Oct 2026 144
06 Aug 2026 Form 4: Gheuens Sarah, Chief Medical Officer

Sold 30,000 shares ($914K)

04 Aug 2026 144
03 Aug 2026 SCHEDULE 13G/A
30 Jul 2026 10-Q
30 Jul 2026 8-K: Results of Operations and Financial Condition

CAMBRIDGE, Mass., July 30, 2026 – Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced financial results and ...

10 Jul 2026 Form 4: Backstrom Jay T., Director

Received 1,447 shares as a grant or award · Exercised 1,447 Restricted stock units

02 Jul 2026 SCHEDULE 13G
02 Jul 2026 Form 4: Gheuens Sarah, Chief Medical Officer

Received 8,375 shares by exercise or conversion · Sold 4,007 shares ($151K)

01 Jul 2026 144
23 Jun 2026 Form 4: Ballal Rahul D., Director

Received 2,816 shares by exercise or conversion · Granted 2,927 Restricted stock units · Granted 14,950 Stock options (right to buy)

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support